Physician profile
Troy Barrow
NPI 1538566336
$1,566.46
in general payments reported to CMS, 2019-2025
14 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2022: $421 · 2023: $490 · 2024: $379 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $485.19 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $295.93 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $151.82 | 2021-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.21 | 2021-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $132.47 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Sunovion Pharmaceuticals INC. | $64.26 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $62.22 | 2022-2024 | Invega Sustenna, Invega Trinza, Invega |
| Indivior INC. | $56.75 | 2023 | Perseris |
| Noven Therapeutics, LLC | $55.01 | 2022 | |
| Vanda Pharmaceuticals INC. | $35.09 | 2022-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $31.58 | 2024 | Abilify Maintena, Rexulti |
| Janssen Biotech, INC. | $19.41 | 2023 | |
| Gilead Sciences, INC. | $18.77 | 2023 | Epclusa |
| E.R. Squibb & Sons, L.L.C. | $15.75 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Barrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.